Corcept Therapeutics Incorporated $(CORT)$ has announced the presentation of data from the treatment phase of its CATALYST trial at the American Diabetes Association's 85th Scientific Sessions, with simultaneous publication in Diabetes Care. The trial, assessing the effects of the cortisol modulator Korlym® in patients with hypercortisolism and difficult-to-control type 2 diabetes, demonstrated significant improvements in glucose control, body weight, and waist circumference, while reducing the need for glucose-lowering medications. The CATALYST trial, which is the largest and most rigorous to date for this purpose, initially identified hypercortisolism in 24% of the 1,057 patients screened. The treatment phase involved 136 patients randomized to receive either Korlym or a placebo over 24 weeks. Results from this phase have already been presented.